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Introduction 
Despite widespread prophylaxis in high risk 
patients (1) acute venous thromboembolism re- 
mains a frequent clinical problem. In a recent North 
American epidemiological survey (2) the annual inci- 
dence of symptomatic deep vein thrombosis (DVT) 
was 48 per 100 000, and that of pulmonary embolism 
(PE), its potentially lethal complication, 23 per 
100 000. Commonly cited figures for PE-associated 
deaths are 100 000 per year in the United States (3), 
and 20 000 per year in the United Kingdom (4). 
While this underlines the need for a low testing 
threshold for pulmonary embolism, it should also be 
kept in mind that the prevalence of PE in patients in 
whom the disease is suspected is only 30% in most 
series (5). The diagnostic gold standard, pulmonary 
angiography (6,7) is costly, invasive and not devoid 
of risks (8), so alternative and more cost-effective 
strategies are clearly warranted. 
This review will focus on the contribution of 
non-invasive diagnostic tests, such as lung scan, 
plasma D-dimer measurement, lower limb venous 
compression ultrasonography (9), and echocardi- 
ography (lo), to the diagnosis of PE. It will also 
emphasize the fundamental role played by clinical 
probability in the interpretation of these test results. 
Indeed, the decision to forego further investigations, 
to prescribe anticoagulant treatment or to perform 
another test, relies on the probability of PE after 
diagnostic testing, which in turn depends on test 
properties (sensitivity and specificity), and on the 
clinical or prior probability of PE (11,12). The diag- 
nostic process which constitutes the general frame for 
this review is depicted diagrammatically in Fig. 1. 
Clinical Presentation of PE and Prior Probability 
Assessment 
Pulmonary embolism usually presents as one of 
three clinical syndromes: pleuritic pain with or 
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without haemoptysis (50% of cases), unexplained 
dyspnoea (30% of cases), or shock (10% of cases) 
(13,14). In the remaining 10% of patients, PE is 
evoked generally because of an abnormal chest X-ray 
(atelectasis, pleural effusion or pleural-based opacity) 
in the context of tachypnoea and/or a history of deep 
vein thrombosis (13,14). As shown in Table 1, the 
sensitivity of a few symptoms, signs, and paraclinical 
findings commonly associated with PE (14,15) is not 
very high. Moreover, they are found with equal 
frequency in patients with suspected PE who turn out 
not to have the disease (14). 
However, despite the poor performance of each 
symptom or sign in predicting PE, an empirical 
assessment integrating these clinical and paraclinical 
elements is surprisingly accurate. In the PIOPED 
study (5), clinical probability was rated before lung 
scan as low (O-19%), indeterminate (20-79%) or high 
(2 80%). Pulmonary embolism was found in only 9% 
of the patients attributed a low clinical probability, 
whereas 68% of patients with a high clinical probabil- 
ity had PE, suggesting the clinicians were more 
successful at ruling out PE than making a positive 
clinical diagnosis. A more recent account (16) involv- 
ing the entire study population confirms the accuracy 
of clinical assessment. Our group has also found a 
fair association between clinical probability and final 
diagnosis in several outpatient cohorts (17-19), even 
though clinical assessment was carried out by internal 
medicine residents, without specific training in 
venous thromboembolism. 
Some attempts have been made to settle the 
unavoidable variability associated with empirical 
assessment by developing clinical prediction scores 
(20-22). A score including only three variables (the 
sum of risk factors for venous thromboembolism, 
presence or absence of chest X-ray abnormalities 
and the respiratory rate) was recently developed and 
validated in our institution in a sample of 300 
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Fig. I The diagnostic process. Post-test probability is 
computed from prior (clinical) probability by Bayes’ theo- 
rem. Three possibilities arise: (1) post-test probability is 
lower than the ‘test’ threshold, the diagnosis may be aban- 
doned without further testing; (2) post-test probability is 
higher than the ‘treatment’ threshold, the patient should be 
treated; (3) post-test probability lies between the ‘test’ and 
‘treatment’ thresholds, a second test should be done. Note 
that the value of the thresholds depends on severity of 
untreated disease, treatment efficacy, complications due to 
treatment and test, and properties of the second test under 
consideration. 
consecutive outpatients with suspected PE (20). It 
was able to correctly classify 74% of patients with a 
sensitivity of 70% and a specificity of 77%, and could 
be summarized in a bedside table. However, it did not 
perform better than empirical assessment (23). 
Overall, this evidence points out that clinical prob- 
ability, assessed either by a score or on empirical 
grounds, though not accurate enough to diagnose 
PE, may be used as prior probability for computing 
posterior probability after diagnostic testing. 
Lung Scan 
The contribution of ventilation-perfusion lung 
scan to the diagnosis of PE has been extensively 
studied (5,24-27). A normal perfusion scan is con- 
sidered to convincingly rule out clinically significant 
PE (28,29). Conversely, a high probability pattern, 
according to the PIOPED criteria, has a high speci- 
ficity for PE (97%) and is widely-accepted as estab- 
lishing PE, in the face of an evocative clinical picture 
(5). In contrast, the prevalence of PE in patients with 
other lung scan findings (very low, low or indetermi- 
nate probability, according to PIOPED criteria), 
varies between 4-30% (5). So these results, which 
occur in approximately 67% of patients, should be 
considered nondiagnostic. The diagnostic utility of 
lung scan is not diminished by pre-existing cardiac or 
pulmonary disease (30), ivith the notable exception of 
chronic obstructive pulmonary disease, a condition 
Table 1 Frequency of symptoms, signs and paraclinical 
findings in patients with and without pulmonary embolism 
PE (%) No PE (%) 
Symptoms 
Dyspnoea 13 12 
Pleuritic pain 66 59 
Cough 31 36 
Leg pain 26 24 
Haemoptysis 13 8 
Signs 
Tachypnoea 70 68 
Tachycardia 35 24 
Temperature > 38.X 7 12 
Signs of DVT 11 11 
Chest radiograph 
Abnormal 84 66* 
Electrocardiogram 
Abnormal 70 - 
Alveolar-arterial oxygen gradient 
>2.6 kPa 86 78 
*P<O.OOl; an abnormal chest radiograph is the only finding 
that was found significantly more frequently in patients with 
pulmonary embolism (PE), in this analysis from which 
patients with pre-existing cardiac or pulmonary disease were 
excluded. Adapted from reference (14). 
in which lung scan is diagnostic in only 10% of 
patients (31). 
Can the predictive value of a nondiagnostic lung 
scan be heightened by combining lung scan result 
and clinical judgment? Figure 2 shows the relation- 
ship between clinical probability of PE and prob- 
ability of PE after lung scan, as computed by means 
of Bayes’ theorem (11,12), each curve representing a 
specific lung scan result. In the presence of a low 
probability lung scan (likelihood ratio 0.4, see 
below), the likelihood of PE is very low up to a 
clinical probability of 15%. However, this likelihood 
is unacceptably high for higher clinical probabilities 
(30% for a clinical probability of 50%). Interest- 
ingly, these theoretical figures are very close to 
those found in the PIOPED study (Table 2) (5). A 
concordant low clinical and lung scan probability 
had a high negative predictive value for PE (Table 
2). In contrast, the prevalence of PE in patients 
with a so-called low probability scan and an in- 
determinate or high clinical probability was 1640% 
(5), underlining the need for abandoning this mis- 
leading term. Hence, a so-called low probability 
lung scan rules out PE only in the presence of a low 
clinical probability, a conjunction which was found 
in 30% of patients with such a lung scan result in 
the PIOPED population (5). 
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Table 2 Likelihood of pulmonary embolism (PE) accord- 
ing to lung scan result and clinical probability of PE 
[PIOPED study, (5)] 
Lung scan probability of PE 
Clinical Normal/ 
probability near normal Low Indeterminate High 
of PE W) WI W) (9/d 
Low (O-0.19) 
Indeterminate 
(0.20-0.79) 
2 4 16 56 
6 16 28 88 
High (0.80-1.0) 0 40 66 96 
Adapted from reference (5). 
A more accurate and useful way of classifying 
lung scan results resorts to the likelihood ratio 
(532). The likelihood ratio (LR) expresses a test’s 
sensitivity and specificity as a single value, and can 
be used in Bayes’ formula to compute post-test 
probability (11,12). The LR for a positive test is the 
true positive rate/false positive rate ratio, and the 
LR for a negative test is the false negative rate/true 
negative rate ratio. Thus, a test with a LR= 1 yields 
an equal number of true and false positives, and 
does not modify the prior probability of disease. In 
contrast, a test with a LR above 10 indicates that a 
positive test is 10 times more likely to be a true 
positive than a false positive, and substantially 
raises the probability of disease. Conversely, a LR 
close to 0 implies a very low false negative rate, and 
renders the disease very unlikely. The LR for lung 
scan results in the PIOPED study (5) were the 
following: high probability, 13.6; indeterminate 
probability, 0.9; low probability, 0.4; and very low 
probability, 0.2. Recently, authors participating in 
the PIOPED study reanalysed the data and 
acknowledged that the predictive value of certain 
findings, which were uniformly classified by 
PIOPED criteria as low or indeterminate probability, 
was variable (33,34), suggesting that a revised classi- 
fication should be considered. The most interesting 
revision, from a diagnostic point of view, is the 
recognition of the relatively high predictive value of a 
unique segmental mismatch. Indeed, the specificity of 
finding one or more mismatched segmental defects 
was 91%, with a sensitivity of 57%, for the entire 
PIOPED population, corresponding to a LR of 6.3. 
Not surprisingly, the specificity of this pattern was 
even higher when considering only those patients 
without any prior cardiopulmonary disease. The 
influence of such a lung scan result on the probability 
of PE can be observed in Fig. 2. 
In summary, lung scan is diagnostic, either normal 
or high probability, in approximately 33% of 
patients; the combination of lung scan and clinical 
probability, by using likelihood ratios and Bayesian 
analysis, may increase the diagnostic efficiency of 
lung scan. 
Plasma Ddimer 
Measuring plasma levels of various markers for the 
activation of coagulation and fibrinolysis, has been 
made easier by the increasing availability of mono- 
clonal antibody-derived assays. The contribution of 
one of these markers, D-dimer, to the diagnosis of 
acute venous thromboembolism has been extensively 
studied (19,35,36). Since D-dimer is a very specific 
degradation product of crosslinked fibrin (37), it was 
hoped that increasing levels would have some speci- 
ficity for venous thromboembolism. In fact, because 
of the high number of conditions which activate 
coagulation and fibrinolysis, such as inflammation, 
cancer, trauma, or surgery, D-dimer has a low 
specificity (45%), and is thus unsuitable for positive 
diagnosis (Fig. 2). On the other hand, when measured 
by an ELISA assay, D-dimer is highly sensitive for 
acute deep venous thrombosis (DVT) or PE. In a 
recent review of nine studies, pooling 908 patients 
with suspected PE (35) the sensitivity of D-dimer 
was 97% (95% CI 95-99). So, a D-dimer test under a 
specific cutoff value (300-5OOpg l- ‘, depending on 
the selected commercial assay) has a high negative 
predictive value for both DVT and PE, virtually 
ruling out PE in the face of a low clinical probability 
(Fig. 2). However, above a clinical probability of 
60%, absence of PE should be confirmed by other 
tests. 
The main limitations to a more widespread use of 
D-dimer in the diagnostic workup of PE, is the 
requirement for the ELISA method. Commercial 
D-dimer ELISA assays come in kits, and are labour- 
intensive, rendering them ill-suited for emergency 
use. The false negative rate of latex tests is too high 
[83% sensitivity among 733 patients suspected of 
DVT, (35)] to replace ELISA assays. Moreover, 
reproducibility between commercially available 
ELISA tests is poor, in part because of the variety of 
monoclonal antibodies, which recognize different 
epitopes of the D-dimer complex (38). Rapid and 
sensitive unitary tests are currently being developed. 
Diagnosis of Deep vein Thrombosis in Suspected PE 
Lower limb DVT accounts for the vast majority of 
pulmonary embolisms (26,39,40). In a series of 
patients with angiographically proven PE, in whom 
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Fig. 2 Relationship between pre- and post-test probability for (a) lung scan, (b) D-dimer and (c) ultrasonography (US) 
(graphic representation of Bayes’ theorem). Results of the lung scan are expressed as likelihood ratios: high probability, 
13.6; single mismatched segment, 6.3; indeterminate probability, 0.9; low probability, 0.4; normal/near-normal, 0.2. The 
dashed line represents the example of a patient with a 50% clinical probability, undergoing lung scan, D-dimer and US 
sequentially. The lung scan result being low probability, the post-test probability is 29%. This in turn becomes the pre-test 
probability for D-dimer. A negative D-dimer would yield a post-test probability of 3% and thus suffice to rule out 
pulmonary embolism (PE) whereas post-test probability with a positive D-dimer would be 42%, leading to perform US. 
With a pre-test probability of 42%, the post-test probability if a deep vein thrombosis were diagnosed by US would be 96%, 
and the patient would be treated without further testing. For the case of a negative US however, the post-test probability 
of PE would still be 22%, and angiography should be performed (see text for further explanation). Note that the shaded area 
in each diagram represents the range of post-test probabilities (644%) for which pulmonary angiography should be 
performed, if the test under consideration is the only available test, or the last of a sequence of tests, before angiography is 
considered. pPE: probability of PE. 
phlebography was systematically performed, DVT two different manifestations of venous thrombo- 
was found in 70% of patients (26). On the other hand, embolism, a single disorder which uniformly requires 
several studies have established the high rate anticoagulant treatment. Therefore, diagnosing 
(approximately 50%) of clinically silent PE in patients DVT in a patient with suspected PE renders 
with DVT, undergoing systematic lung scan (4143). further testing, particularly pulmonary angiography, 
This evidence underscores that DVT and PE are unnecessary. 
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Lower limb B-mode venous compression ultra- 
sonography (US) has widely replaced phlebography 
in diagnosing proximal DVT (4446). Sensitivity and 
specificity of ultrasonography for symptomatic proxi- 
mal DVT are respectively 90% and above 95%. Given 
a 70% prevalence of detectable DVT in suspected PE 
(26), US could theoretically yield a diagnosis of 
venous thromboembolism in approximately 60% of 
patients with PE. Even though patients with PE are 
frequently asymptomatic for DVT, specificity should 
remain high, by analogy with other situations in 
which US was used for screening in asymptomatic 
patients (47,48). In a recently completed prospective 
series involving 308 consecutive outpatients with sus- 
pected PE, US was positive in 66/109 patients with 
PE, yielding a sensitivity of 61% (17). Specificity was 
97%. Two retrospective series examined the preva- 
lence of DVT in patients having undergone both lung 
scan and US for suspected PE. The sensitivity of US 
was 3649% for patients with a high probability 
lung scan and only 1619% for patients with a 
nondiagnostic lung scan (49-50). This difference was 
also noted in our series, sensitivity of US being as 
high as 70% in cases with a high probability lung scan 
and only 48% in patients with nondiagnostic scans 
(17). Thus, due to high specificity, a positive US has 
a high positive predictive value for venous thrombo- 
embolism (Fig. 2). However, a negative US has a low 
negative predictive value, and is therefore insufficient 
to rule out venous thromboembolism in the context 
of suspected PE. 
Impedance plethysmography (IPG) has also been 
widely-used in the evaluation of proximal DVT. A 
recent overview (51), pooling the results in 2978 
patients, determined a 90% sensitivity of IPG for 
proximal DVT in symptomatic patients. Although 
the sensitivity of IPG has recently been reported to be 
lower (65%) in certain clinical settings (52), specificity 
is consistently high [94% (51,52)]. The characteristics 
of IPG are therefore very similar to those of US, and 
some authors advocate it as a substitute for US in the 
diagnostic workup of suspected PE (53,54). 
In summary, finding a DVT by US or IPG in a 
patient with suspected PE obviates the need for 
invasive testing, and warrants anticoagulant treat- 
ment. In contrast, the sensitivity of US or IPG in this 
situation is low, so that a negative test does not rule 
out venous thromboembolism. 
Echocardiography 
The contribution of echocardiography to the 
diagnosis of PE is most often indirect (10). Right 
ventricular dilatation and/or hypokinesis, abnormal 
septal position, reduced left ventricular size or 
increased right ventricular/left ventricular diameter 
ratio may all result from the right ventricular strain 
caused by acute pulmonary hypertension. Pulmonary 
hypertension can be assessed in patients with tricus- 
pid regurgitation, by measuring the regurgitation 
flow velocity (55). However, as was already known 
from angiographic data (56), these haemodynamic 
consequences only occur if more than 30% of 
the pulmonary vasculature is occluded (10,57). 
Therefore, these echocardiographic signs have a 
low sensitivity for small pulmonary emboli (58). 
Moreover, they are nonspecific, and should be inter- 
preted with caution in patients with known cardiac 
or pulmonary disease associated with chronic 
pulmonary hypertension. 
Direct visualization of a thrombus in the right 
heart chambers or in the pulmonary artery by trans- 
thoracic echocardiography has been repeatedly 
reported (59), but remains an exceptional event. This 
situation will probably be encountered more fre- 
quently with the wider use of transoesophageal 
echocardiography (60). 
In summary, although no series has established the 
contribution of systematic echocardiography in sus- 
pected PE, it is probably not very sensitive, and a 
negative echocardiography should not be used to rule 
out the diagnosis. Conversely, in the absence of 
chronic pulmonary hypertension, signs of pulmonary 
hypertension may be evocative of PE in an appropri- 
ate clinical context. Lastly, echocardiography is, very 
helpful for differential diagnostic purposes (61) espe- 
cially with heart failure, cardiogenic shock, aortic 
dissection and tamponade. 
Pulmonary Angiography 
Pulmonary angiography remains the gold stan- 
dard for PE diagnosis (5,6), providing it is performed 
with an appropriate technique, including several pro- 
jections and selective injections into the pulmonary 
circulation [peripheral intravenous injection has 
proved disappointing, despite the use of digital sub- 
traction angiography (62)]. However, the limitations 
of angiography should be recognized. Angiography 
is costly and invasive. In the PIOPED study, the 
mortality associated with angiography was 0.5% (S), 
and 0.3% when pooling PIOPED and two other 
important series (63,64). Major complication rate is 
approximately lo?, and minor complications occur in 
2% of patients (8,63,64). Moreover, interpretation of 
pulmonary angiograms is difficult, as was evidenced 
by the frequent disagreement between readers in 
analysing angiograms in the PIOPED series (5). 
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Experts disagreed on the presence of PE in 8% of 
patients and on the absence of PE in 17% of patients. 
Even after adjudication by a panel of experts, 3% of 
angiograms were rated nondiagnostic (5). On follow- 
up, 0.6% of patients with a negative angiogram had 
PE (8). Thus, it should be kept in mind that even an 
angiogram can be falsely positive or negative, and 
should be interpreted according to the clinical 
probability of PE. 
Diagnostic Strategies for PE 
There is general agreement that ventilation- 
perfusion lung scan is the first step in the diagnosis of 
PE, where nuclear medicine facilities are available, 
and on the diagnostic value of a normal or high 
probability lung scan. The traditional view that 
patients with a nondiagnostic lung scan should pro- 
ceed to pulmonary angiography (7), is changing due 
to the advent of the noninvasive tests described 
above, and the increasing recognition of the useful- 
ness of clinical assessment. Most authors 
(4,53,54,65,66) agree on the usefulness of performing 
IPG or US in such patients, thereby obviating the 
need for angiography when DVT is diagnosed. Clini- 
cal probability is also included in some of these 
strategies (54,65), in which case the likelihood of PE 
according to clinical probability and lung scan in the 
PIOPED study (5), guides the prescription of pulmo- 
nary angiography, in association with the result of 
IPG or US. For instance, the post-test probability of 
PE in patients with an indeterminate clinical prob- 
ability and a low probability lung scan was 16% in 
the PIOPED study (Table 2); a negative US or IPG, 
with an ability to detect 50% of DVTs in patients 
with PE, and a specificity over 90% for DVT, would 
lower the post-test probability to 9%, a figure consid- 
ered low enough by the authors (54) to withhold 
treatment and forego pulmonary angiography. In 
contrast, if clinical probability of PE was high with a 
similar lung scan result, the post-test probability of 
PE would be 40% (Table 2), and still as high as 25% 
despite a negative IPG or US, because of the low 
predictive value of these tests, so pulmonary angiog- 
raphy should be performed (54). 
The only totally noninvasive diagnostic strategy is 
that of Hull et al. (66,67), in which patients with 
nondiagnostic lung scans were screened by IPG, 
performed on days 1, 2, 3, 5, 7, 10 and 14. The 
rationale for serial testing was the search for a 
proximal DVT evolving from a distal DVT (68) that 
could have been missed by initial IPG, this technique 
being relatively insensitive to distal DVT. Patients 
with a positive IPG, either initially or on serial 
V/Q scan 
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B-mode 
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Fig. 3 Flow-chart representing the diagnostic strategy for 
pulmonary embolism in our institution. 
Table 3 Data necessary to define the test and treatment 
thresholds in the diagnostic process 
% 
Mortality of PE 
Untreated 
Treated 
Angiography 
Sensitivity 
Specificity 
Mortality 
Morbidity 
Anticoagulant treatment 
Mortality* 
Morbidity 
30 
8 
90 
95 
0.5 
3 
1.4 
16 
*Combining a 7-day heparin and 6-month coumarin treat- 
ment. For computing utility values, we considered 10 mor- 
bid events as equivalent to 1 lethal event. So, expressed as 
‘mortality-equivalents’, a 6-month anticoagulant treatment 
would amount to a 3% reduction of survival [1.4%+(16%/ 
lo)]. Adapted from reference (9). 
testing, were treated with anticoagulants after confir- 
mation by venography. Among 711 patients with a 
nondiagnostic lung scan in the more recent series 
(66), IPG was initially positive in 68 patients, and 
on serial testing in 16 patients. In case of a negative 
IPG, patients were not treated and followed up 
during 3 months. This strategy appeared safe, with 
a very low rate of thromboembolic events on 
follow-up [1.9% (95% CI Og-3.0)]. Obviously, US 
could probably be substituted for IPG in this 
protocol. However, this strategy is of questionable 
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Fig. 4 Decision tree representing three possible strategies for suspected pulmonary embolism (No treatment, Angiography 
and Treatment). Occurrence of possible outcomes depends on following probabilities: pl =probability of PE; p2= I-pl; 
p3 =mortality due to angiography; prl=sensitivity of angiography; and p5=specificity of angiography. Probability of PE 
may correspond to clinical probability of PE, if angiography is the only available test, or to the posterior probability of PE 
after a sequence of noninvasive tests. The theoretical computation of utilities, corresponding to the value of each outcome, 
is described for each outcome. PE: pulmonary embolism, noPE: no pulmonary embolism, TTT: treatment, noTTT: no 
treatment, Angio: angiography, mortPE: mortality of untreated PE, mortPE ttt: mortality of treated PE, r ttt: morbidity 
and mortality of a 6-month anticoagulant treatment, r angio: morbidity and mortality of pulmonary angiography. 
cost-effectiveness, since only 2.3% of the patients with their influence on pre-test probability, according to 
a nondiagnostic scan turned out to have a DVT on Bayes’ theorem (Fig. 2). The advantage of these 
serial testing. Moreover, this approach did not representations is to allow an easy assessment of 
include clinical probability. post-test probability of PE, whatever the selected 
The decision-making process in our institution combination and sequence of tests. Indeed, test avail- 
(9,17) combines clinical probability, lung scan, ability may differ in various clinical settings, but the 
D-dimer and US, with angiography only performed diagnostic reasoning remains unchanged (Fig. 1). 
in patients with an inconclusive noninvasive work- The clinical probability is the basis for interpreting 
up (Fig. 3). In a recent trial including consecutive the first test’s result. If posterior probability of PE at 
outpatients, the non-invasive component of this that stage is both too high to withhold treatment, and 
strategy allowed a definitive diagnosis in 62% of too low to treat the patient, a second test will be 
patients with nondiagnostic lung scans (17). performed, the posterior probability after the first 
test becoming the prior probability for the second 
Decision Analysis test. This process is pursued until the probability of 
We reviewed the properties of various diagnostic PE is sufficiently low to withhold, or high enough to 
tests for PE, and provided graphic representations of warrant, anticoagulant treatment (Fig. 1). These 
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‘test’ and ‘treatment’ thresholds obviously depend on 
a balance between the severity of the untreated 
disease, the efficiency of treatment, the complications 
associated with both treatment and invasive tests, 
and the properties of the test. Relevant figures in the 
context of PE are listed in Table 3. 
The ability of intuitive thinking to take into 
account all the variables of such a complex problem 
is limited. Therefore, we chose to use decision 
analysis, a technique allowing formal analysis of 
these thresholds (11,69,70). Let us consider a very 
simple model, considering only three strategies in a 
suspicion of PE, i.e. withholding treatment (No treat- 
ment), performing angiography and treating only if 
the angiogram is positive (Angiography) or treating 
the patient without an angiogram (Treatment). These 
strategies can be represented as a decision tree 
(Fig. 4). Three branches, corresponding to the three 
strategies, originate from ‘decision node’ (0, Fig. 4). 
For each of these branches, all possible subsequent 
events and outcomes are described, stemming from 
‘chance nodes’ (0, Fig. 4). The occurrence of these 
events is governed only by chance or probabilities, 
i.e. (pl) the clinical probability of PE; (~2) the 
probability of dying from pulmonary angiography; 
(~3) the probability of an angiogram being positive in 
presence of PE (sensitivity of angiography); and (p4) 
the probability of an angiogram being negative in the 
absence of PE (specificity of the test). In order to 
select the preferred strategy, each outcome is assigned 
a specific value, also called ‘utility’ in decision analy- 
sis, to account for the fact that the various outcomes 
are not equally desirable. The utility value chosen in 
this model (9) is the proportion of surviving patients 
at 6 months, and can be calculated as described in 
Fig. 4, using the data from Table 3. Lastly, the global 
expected value of each considered option (the 
‘expected utility’) is computed by combining prob- 
abilities and utilities for each outcome. By definition, 
the strategy with the highest expected utility, i.e. 
yielding the highest proportion of living patients at 6 
months, will be preferred [for more detail on decision 
analysis models, see ref. (1 l)]. 
The expected utility may then be plotted against 
the clinical probability of PE (Fig. 5), allowing a 
clear definition of the thresholds. Indeed, the ‘test’ 
threshold corresponds to the clinical probability of 
PE for which the expected utility of the No treatment 
and Angiography strategy is identical, i.e. 6% 
(Fig. 5). Consequently, the probability of PE prior 
to angiography should be lower than 6% in order to 
withhold treatment without further testing. It should 
be emphasized that the probability of PE prior to 
angiography (or ‘pre-angiographic’ probability of 
Pre-angiographic probability of PE 
Fig. 5 The three continuous lines represent the expected 
utility of three strategies: No Treatment (O), Angiography 
(baseline) (0), and Treatment (a), according to probability 
of pulmonary embolism (PE) prior to angiography (the 
so-called pre-angiographic probability of PE). The ‘test’ 
threshold is the probability of PE value for which the 
expected utility of No treatment and Angiography is iden- 
tical, i.e. 0.06 or 6%. The ‘treatment’ threshold is 44%. As in 
Fig. 2, the range of pre-angiographic probabilities for which 
angiography should be performed is highlighted by a 
shaded area. The dashed line represents the expected utility 
of an Angiography (A) strategy, considering a higher 
sensitivity and specificity for angiography than baseline 
values (i.e. 99 and 99%). This example of sensitivity analysis 
shows that even using those figures highly favourable to 
angiography, the threshold for treating without performing 
an-angiography remains lower than would be thought 
intuitivelv. i.e. 70%. In contrast, the ‘test’ threshold remains 
virtually &affected. 
PE) can either represent the clinical probability of 
PE, if angiography is the only test available, or the 
posterior probability of PE, after a combination of 
noninvasive tests. The ‘treatment’ threshold is 44% 
(Fig. 5), which might seem surprisingly low since it 
follows that any patient with a pre-angiographic 
probability higher than 44% should be treated with- 
out an angiogram. This is more a consequence of the 
10% false negative rate we assumed for angiography 
in the decision model, than of the mortality and 
morbidity associated with the procedure. Indeed, a 
false negative angiogram entails the mortality risk of 
untreated PE, 30% (71,72), whereas the mortality 
of an undue anticoagulant treatment is only 
approximately 1% (73). 
Each value in the decision model can be varied, in 
order to define which of the data have the most 
influence on the preference or ranking of strategies. 
This process is named ‘Sensitivity Analysis’ 
(11,69,70). What would be the influence on the ‘test’ 
and ‘treatment’ thresholds of adopting a much high 
value of sensitivity and specificity for angiography 
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(99% and 99%, respectively, Fig. 4)? The ‘test’ thresh- 
old is virtually unchanged (4%) and the ‘treatment’ 
threshold increases to 70%, which is still lower than 
most clinicians would determine by intuition alone. 
Thus, the decision to treat without performing 
angiography in presence of a high clinical probability 
stands, even when favouring angiography in the 
model, and thus appears robust. In summary, deci- 
sion analysis is a precious tool for defining thresh- 
olds. Moreover, it allows a critical appraisal of these 
thresholds by means of sensitivity analysis. 
Conclusion 
The diagnosis of PE has certainly been made easier 
and less invasive in recent years. A more precise 
assessment of the diagnostic performance of lung 
scan, the wide acceptance of a new concept, venous 
thromboembolism, implying a role for the diagnostic 
tests DVT in suspected PE, and the development of 
highly sensitive D-dimer assays, have all significantly 
contributed to this progress. However, the most 
significant conceptual advance in our view is the 
recognition of the paramount importance of clinical 
assessment in the diagnostic process, and the success- 
ful application of this concept to the field of PE. 
Moreover, decision analysis is of great assistance in 
decision-making, allowing a formal determination of 
meaningful post-test probability thresholds. 
10. 
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